Clinical Trials Logo

Fascioliasis clinical trials

View clinical trials related to Fascioliasis.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06367361 Not yet recruiting - Fascioliasis Clinical Trials

One and Two Doses of Oxfendazole Versus a Schedule of Two Doses of Triclabendazole in Chronic Fascioliasis

Start date: July 2024
Phase: Phase 2
Study type: Interventional

Randomized clinical trial comparing the efficacy and safety of oxfendazole at 20 mg/kg per dose in one and two dose regimens with a two-dose regimen of triclabendazole at 10 mg/kg in an endemic region of the highlands of Peru. Children and adults with fascioliasis in rural communities will be screened for inclusion and exclusion criteria and a total of 336 subjects (112 per study arm) with chronic Fasciola infection will be enrolled and assigned randomly to the study arms in a 1:1:1 ratio. The primary efficacy (cure and egg reduction) endpoints will be assessed on day 7 and 30 post treatment. The secondary safety endpoint visits will be performed in days 0, 3, 7 and 30 post-treatment and Population PK modeling studies will be performed in the first 24 hours after the first dose of oxfendazole.

NCT ID: NCT03869788 Not yet recruiting - Fascioliasis Clinical Trials

Parasitological Evaluation of Fascioliasis in Clinically Suspected Patients .

Start date: September 1, 2019
Phase:
Study type: Observational [Patient Registry]

WHO considers foodborne trematodes as neglected tropical diseases. Fascioliasis is the most widely distributed trematode reported from over 81 countries around the world it imposes its highest burden in developing countries